Filtered By:
Vaccination: Cervical Cancer Vaccine
Countries: China Health
This page shows you your search results in order of date.
Order by Relevance | Date
Total 51 results found since Jan 2013.
Frequency of health care provider recommendations for HPV vaccination: a survey in three large cities in China
DISCUSSION: The frequency of HCPs' recommendations for HPV vaccination in China was much lower than that in many developed countries. To enhance the recommendation frequency, medical institutions should help HCPs gain more knowledge of HPV and master communication skills. At the same time, the government should take measures to enhance the accessibility of HPV vaccines. The media should help to alleviate people's concerns and encourage them to face up sexual health.PMID:37497028 | PMC:PMC10366465 | DOI:10.3389/fpubh.2023.1203610
Source: Cancer Control - July 27, 2023 Category: Cancer & Oncology Authors: Yimeng Mao Yuchen Zhao Lingyun Zhang Jie Li Abu S Abdullah Pinpin Zheng Fan Wang Source Type: research
Head-to-head immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil 9 in women aged 18-26 years in China: a randomised blinded clinical trial
This study aimed to compare the immunogenicity of the E coli-produced HPV 9-valent vaccine Cecolin 9 (against HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58) with Gardasil 9.METHODS: This was a randomised, single-blind trial conducted in China. Healthy non-pregnant women aged 18-26 years, who were not breastfeeding and with no HPV vaccination history, were enrolled in the Ganyu Centre for Disease Control and Prevention (Lianyungang City, Jiangsu Province, China). Women were stratified by age (18-22 years and 23-26 years) and randomly assigned (1:1) using a permutated block size of eight to receive three doses of Cecolin 9 or Ga...
Source: Cancer Control - July 20, 2023 Category: Cancer & Oncology Authors: Feng-Cai Zhu Guo-Hua Zhong Wei-Jin Huang Kai Chu Li Zhang Zhao-Feng Bi Kong-Xin Zhu Qi Chen Ting-Quan Zheng Ming-Lei Zhang Sheng Liu Jin-Bo Xu Hong-Xing Pan Guang Sun Feng-Zhu Zheng Qiu-Fen Zhang Xiu-Mei Yi Si-Jie Zhuang Shou-Jie Huang Hui-Rong Pan Ying-Y Source Type: research
Promotion of human papillomavirus vaccination among Chinese men who have sex with men: abridged secondary publication
Hong Kong Med J. 2023 Jun;29 Suppl 3(3):9-15.NO ABSTRACTPMID:37357584
Source: Hong Kong Med J - June 26, 2023 Category: General Medicine Authors: Z Wang J T F Lau P P K Lam P Chan F Fong P K H Mo Source Type: research
An investigation on cervical cancer and human papillomavirus vaccine knowledge, and analysis of influencing factors for choosing domestic or imported 2vHPV vaccine among females in Shenzhen, China
In conclusion, eligible female recipients had a high degree of knowledge regarding cervical cancer and HPV vaccine, education level and occupation were the most important factors for scores. Domestic 2vHPV vaccine was more widely utilized than imported, manufacturer, efficacy, safety, cognitive approach, public opinion, convenient acquisition, and knowledge reserve had an impact on selection for recipients, while price and doctor's suggestion did not.PMID:37350143 | DOI:10.1080/21645515.2023.2225389
Source: Cancer Control - June 23, 2023 Category: Cancer & Oncology Authors: Linxiang Chen Fangfang Lu Ziqi Wang Hanqing Chen Mianling Chen Chunmiao Peng Kangming Chen Cuili Chen Huawei Xiong Xu Xie Source Type: research
The efficacy of human papillomavirus prophylactic vaccination after conization in preventing cervical intraepithelial neoplasia recurrence: A prospective observational study in China
Eur J Obstet Gynecol Reprod Biol. 2023 Apr 19;286:10-15. doi: 10.1016/j.ejogrb.2023.04.014. Online ahead of print.ABSTRACTHigh-risk human papillomavirus (hrHPV) infection is the cause of most cervical cancers. Since therapeutic vaccines are not yet available for clinical practice, the administration of HPV prophylactic vaccines in patients with cervical intraepithelial neoplasia (CIN) arouses great interest and its value after excisional treatment of CIN remains unclear. We conducted this prospective cohort study to evaluate the impact of HPV prophylactic vaccination on preventing women from subsequent infection and cervic...
Source: Reproductive Biology - May 9, 2023 Category: Reproduction Medicine Authors: Ming Chen Cheng Li Qiulin Cui Chengli Zhou Peisong Chen Shuzhong Yao Source Type: research
Safety and immunogenicity of a pichia pastoris-expressed bivalent human papillomavirus (types 16 and 18) L1 virus-like particle vaccine in healthy Chinese women aged 9-45 years: A randomized, double-blind, placebo-controlled phase 1 clinical trial
CONCLUSION: The pichia pastoris-expressed bivalent HPV vaccine was safe and immunogenic in Chinese females aged 9-45 years. The low dosage (0.5 mL) was selected for further immunogenicity and efficacy study.PMID:37061370 | DOI:10.1016/j.vaccine.2023.04.009
Source: Vaccine - April 15, 2023 Category: Allergy & Immunology Authors: Juan Li Li-Wei Shi Bang-Wei Yu Li-Rong Huang Ling-Yun Zhou Li Shi Zhi-Wei Jiang Jie-Lai Xia Xuan-Yi Wang Rong-Cheng Li Lin Yuan Yan-Ping Li Chang-Gui Li Source Type: research
Knowledge of Cervical Cancer and HPV, and Willingness to Receive HPV Vaccination Among 20-45-Year-Old Women - Six Provinces, China, 2018
China CDC Wkly. 2023 Mar 3;5(9):201-205. doi: 10.46234/ccdcw2023.036.ABSTRACTWHAT IS ALREADY KNOWN ABOUT THIS TOPIC?: Cervical cancer is a significant public health problem with approximately 570,000 cases and 311,000 deaths occurring in 2018 globally. It is imperative to raise awareness of cervical cancer and human papillomavirus (HPV).WHAT IS ADDED BY THIS REPORT?: Compared to previous studies, this is one of the largest cross-sectional studies of cervical cancer and HPV in Chinese adult females in recent years. We found that knowledge level of cervical cancer and HPV vaccine was still inadequate among women aged 20-45 y...
Source: Cancer Control - April 3, 2023 Category: Cancer & Oncology Authors: Di Gao Gengli Zhao Jiangli Di Xiaosong Zhang Linhong Wang Source Type: research
Prevalence of High-Risk Human Papillomavirus in Cervical Intraepithelial Neoplasia in the Pre-Vaccine Era - China, 2017-2018
China CDC Wkly. 2022 Dec 2;4(48):1083-1087. doi: 10.46234/ccdcw2022.218.ABSTRACTWHAT IS ALREADY KNOWN ABOUT THIS TOPIC?: Human papillomavirus (HPV) type-specific strategies play a key role in the prevention of cervical intraepithelial neoplasia (CIN), but evidence on the HPV type-specific prevalence in CIN is limited.WHAT IS ADDED BY THIS REPORT?: This multicentric study estimates the prevalence of high-risk HPV types in CIN cases and the associations of HPV infection patterns with high-grade CIN in China in 2017-2018.WHAT ARE THE IMPLICATIONS FOR PUBLIC HEALTH PRACTICE?: Population-based prevention strategies should give ...
Source: Cancer Control - February 8, 2023 Category: Cancer & Oncology Authors: Heling Bao Weihong Chen Xiaosong Zhang Hui Bi Yun Zhao Liwen Fang Shu Cong Feng Tan Linhong Wang Source Type: research
Knowledge, attitude, and perception regarding HPV-related diseases and vaccination among the general public in Guizhou Province of China
CONCLUSION: Guizhou residents had poor knowledge of HPV-related issues. The percentage of healthcare workers who achieved acceptable knowledge levels was one-half or less. The increasing HPV prevalence and cervical cancer incidence can be contained if more affordable vaccines are developed and the low knowledge levels pervading young adults and medical staff is eliminated.PMID:36610933 | DOI:10.1016/j.vaccine.2022.12.027
Source: Vaccine - January 7, 2023 Category: Allergy & Immunology Authors: Luhong Xie Ji Ren Shaoju Min Xiaoyu Zhu Dianqin Xu Kun Qiao Xiaowei Chen Min Liu Ziwen Xiao Yujie Tan Source Type: research
